What's breaking now, across thousands of outlets.
(RTTNews) - British drug major AstraZeneca Plc (AZN, AZN.L) announced Monday that it is discontinuing the eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer or mNSCLC, based on the recommendation of the Independent Data Monitor
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
KOTA KINABALU, Aug 17 (Bernama) -- The Federal Government has approved RM1.57 billion under the First Rolling Plan of the 13th Malaysia Plan (MP13) to help fulfil commitments under the Malaysia…
A study in selected care homes in the Greater Accra Region has found a high prevalence of drug-resistant urinary pathogens among Ghanaian elderly.
On Friday, the NIH released an RFI (request for Information) on a proposed new format for reporting the scores of grant applications determined by study sections.
What began as a swollen eye has turned into a life-altering battle against a rare tumour.
Tokyo, Aug. 17 (Jiji Press)--Nearly 60 pct of people in Japan concerned about sweating have given up certain activities, a joint survey by three pharmaceutical firms found.
